Clik here to view.
Can-Fite preparing protocol for advanced psoriasis trial
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) is preparing the protocol for its next advanced psoriasis trial with its CF101 oral drug candidate, even though an earlier Phase 2/3 study did not meet its...
View ArticleClik here to view.
Can-Fite gets FDA fast track for liver cancer drug
The FDA has granted Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, fast track designation as a second line treatment for hepatocellular carcinoma (HCC), the most common form of...
View ArticleClik here to view.
EMA grants orphan designation to Can-Fite’s CF102
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) oncology drug candidate, CF102, has been granted orphan drug designation by the European Medicines Agency (EMA) for the indication of hepatocellular...
View ArticleClik here to view.
Can-Fite BioPharma in registered direct offering
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has entered into definitive agreements with existing institutional investors to receive gross proceeds of about $4.8-million. The company will issue...
View ArticleClik here to view.
MOA of Can-Fite’s CF602 can improve sexual dysfunction
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its CF602 drug candidate showing a defined mechanism of action in erectile dysfunction similar to sildenafil (Viagra) in a...
View ArticleClik here to view.
Can-Fite expands development of CF102 into NASH
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded...
View ArticleClik here to view.
Can-Fite unit completes enrollment in glaucoma Phase 2 trial
Dr. Pnina Fishman Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTCQB:OPLI), has completed enrollment of 88 patients in its Phase 2 trial of CF101, an oral treatment for...
View ArticleClik here to view.
Can-Fite gets patent in Japan for CF101
The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine...
View ArticleClik here to view.
Can-Fite submits Phase 3 protocol for RA study
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted its Phase 3 clinical study protocol to the Institutional Review Board of Barzilai Medical Center in Israel and will file similar submissions...
View ArticleClik here to view.
Can-Fite unveils clinical milestones for 2016
Dr. Pnina Fishman Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has announced its anticipated clinical milestones for 2016. “We are very encouraged by the clinical and preclinical data from each of our...
View ArticleClik here to view.
Can-Fite receives patent notice for sexual dysfunction drug
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. The...
View ArticleClik here to view.
Can-Fite CEO to chair cancer conference session
Dr. Pnina Fishman, CEO of Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) will chair the plenary session titled, “Drugs Targeting Adenosine Receptors,” at the 2016 Keystone Symposia J5 in Vancouver,...
View ArticleClik here to view.
Can-Fite reports preclinical data in erectile dysfunction
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its drug candidate, CF602, showing statistically significant full recovery from erectile dysfunction after one single dose...
View Article
